| Stage | MSGS | % of rev | DIS | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $279M | 100.00% | $25.2B | 100.00% | DIS ×90.58 |
| Gross profit | $111M | 39.80% | $10.1B | 40.17% | DIS +0.4pp |
| Operating income | $32M | 11.53% | $4.8B | 18.85% | DIS +7.3pp |
| Pre-tax income | $34M | 12.08% | $3.6B | 14.44% | DIS +2.4pp |
| Net income | $28M | 10.15% | $2.8B | 11.26% | DIS +1.1pp |
| Stage | MSGS | DIS | Gap · A − B |
|---|---|---|---|
| Revenue | $279M100.00% | $25.2B100.00% | DIS ×90.58 |
| Gross profit | 39.80%$111M | 40.17%$10.1B | DIS +0.4pp |
| Operating income | 11.53%$32M | 18.85%$4.8B | DIS +7.3pp |
| Pre-tax income | 12.08%$34M | 14.44%$3.6B | DIS +2.4pp |
| Net income |
| 10.15%$28M |
| 11.26%$2.8B |
| DIS +1.1pp |
No shared counterparties.